Gilead paid $1.275B for HCXT-2001, a phase 1 IL-23 inhibitor with no clinical data, targeting inflammatory diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results